Annual Drug Patent Expirations for LUMAKRAS Lumakras is a drug marketed by Amgen Inc and is included in one NDA. […]
Source
Annual Drug Patent Expirations for ARIKAYCE+KIT Arikayce Kit is a drug marketed by Insmed Inc and is included in one […]
Source
Annual Drug Patent Expirations for RUBRACA Rubraca is a drug marketed by Zr Pharma and is included in one NDA. […]
Source
New patent expiration for Zr Pharma drug RUBRACA Read Post »
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd […]
Source
New tentative approval for Alembic drug dabigatran etexilate mesylate Read Post »
A strong patent portfolio is at the core of branded pharmaceutical firms. Accordingly, one way to assess the relative strength […]
Source
Which pharmaceutical companies have the largest patent portfolios? Read Post »
In the rapidly evolving landscape of biosimilars, intellectual property (IP) strategy is paramount. Biosimilar manufacturers face unique challenges, including navigating […]
Source
Cracking the Biosimilar Code: A Deep Dive into Effective IP Strategies Read Post »
Intellectual property (IP) strategy plays a crucial role in the biotechnology industry, where protecting valuable assets and driving innovation are
Pediatric formulations present unique challenges in terms of ensuring the safety and efficacy of medications for young patients. One of the most critical aspects of pediatric formulation development is the selection of appropriate excipients. Excipient…
Pediatric formulations present unique challenges in terms of ensuring the safety and efficacy of medications for young patients. One of the most critical aspects of pediatric formulation development is the selection of appropriate excipients. Excipient…
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd […]
Source
New tentative approval for Alembic drug dabigatran etexilate mesylate Read Post »
Get new actionable insights and updates from BiotechBlog
